8G8 Stock Overview
CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CS Medica A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.68 |
| 52 Week High | DKK 1.61 |
| 52 Week Low | DKK 0.25 |
| Beta | -0.96 |
| 11 Month Change | -35.92% |
| 3 Month Change | 48.25% |
| 1 Year Change | 74.23% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 56.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8G8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.8% | 1.7% | 1.8% |
| 1Y | 74.2% | -11.1% | 13.8% |
Return vs Industry: 8G8 exceeded the German Pharmaceuticals industry which returned -11.1% over the past year.
Return vs Market: 8G8 exceeded the German Market which returned 13.8% over the past year.
Price Volatility
| 8G8 volatility | |
|---|---|
| 8G8 Average Weekly Movement | 28.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8G8's share price has been volatile over the past 3 months.
Volatility Over Time: 8G8's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 9 | Lone Henriksen | www.cs-medica.com |
CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis. It offers gels for psoriasis, arthritis, protective nasal, and wound healing; and CBD anti-hair loss serum, as well as sleep nasal sprays and pain patches. The company primarily offers its products under the CANNASEN brand name.
CS Medica A/S Fundamentals Summary
| 8G8 fundamental statistics | |
|---|---|
| Market cap | €9.38m |
| Earnings (TTM) | -€1.65m |
| Revenue (TTM) | €625.36k |
22.9x
P/S Ratio-8.7x
P/E RatioIs 8G8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8G8 income statement (TTM) | |
|---|---|
| Revenue | DKK 4.67m |
| Cost of Revenue | DKK 2.85m |
| Gross Profit | DKK 1.81m |
| Other Expenses | DKK 14.12m |
| Earnings | -DKK 12.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 38.81% |
| Net Profit Margin | -263.84% |
| Debt/Equity Ratio | 676.5% |
How did 8G8 perform over the long term?
See historical performance and comparison